Scolaris Content Display Scolaris Content Display

Cochrane Database of Systematic Reviews

Primaquine at alternative dosing schedules for preventing relapse in people with Plasmodium vivax malaria

Esta versión no es la más reciente

ver la versión actual 19 agosto 2020

Información

DOI:
https://doi.org/10.1002/14651858.CD012656Copiar DOI
Base de datos:
  1. Cochrane Database of Systematic Reviews
Versión publicada:
  1. 04 mayo 2017see what's new
Tipo:
  1. Intervention
Etapa:
  1. Protocol
Grupo Editorial Cochrane:

  1. Grupo Cochrane de Enfermedades infecciosas

Copyright:
  1. Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Cifras del artículo

Altmetric:

Citado por:

Citado 0 veces por enlace Crossref Cited-by

Contraer

Autores

  • Rachael Milligan

    Correspondencia a: Cochrane Infectious Diseases Group, Liverpool School of Tropical Medicine, Liverpool, UK

    [email protected]

  • André Daher

    Research and Reference Laboratories, Oswaldo Cruz Foundation (FIOCRUZ), Rio de Janeiro, Brazil

  • Patricia M Graves

    College of Public Health, Medical and Veterinary Sciences, James Cook University, Cairns, Australia

Contributions of authors

Patricia Graves (PMG), Paul Garner (CIDG Co‐ordinating Editor) and Rachael Milligan (RM) contributed to the conception of the research question.
All protocol authors contributed to the protocol design and approved the final version.

Sources of support

Internal sources

  • Liverpool School of Tropical Medicine, UK.

External sources

  • Department for International Development, UK.

    Grant number: 5242

Declarations of interest

RM has no known conflicts of interest.
AD has no known conflicts of interest.
PMG has no known conflicts of interest.

Acknowledgements

We are grateful to Vittoria Lutje, the Information Specialist of the Cochrane Infectious Diseases Group (CIDG) for help with the literature search strategy. We thank Marty Richardson, CIDG statistician, for help with the data collection and analysis strategy. Rachael Milligan is supported by the Effective Health Care Research Consortium. This Consortium and the CIDG editorial base are funded by UK aid from the UK Government for the benefit of developing countries (Grant: 5242). The views expressed in this Cochrane protocol do not necessarily reflect UK government policy.

Version history

Published

Title

Stage

Authors

Version

2020 Aug 19

Primaquine alternative dosing schedules for preventing malaria relapse in people with <i>Plasmodium vivax</i>

Review

Rachael Milligan, André Daher, Gemma Villanueva, Hanna Bergman, Patricia M Graves

https://doi.org/10.1002/14651858.CD012656.pub3

2019 Jul 05

Primaquine at alternative dosing schedules for preventing relapse in people with <i>Plasmodium vivax</i> malaria

Review

Rachael Milligan, André Daher, Patricia M Graves

https://doi.org/10.1002/14651858.CD012656.pub2

2017 May 04

Primaquine at alternative dosing schedules for preventing relapse in people with <i>Plasmodium vivax</i> malaria

Protocol

Rachael Milligan, André Daher, Patricia M Graves

https://doi.org/10.1002/14651858.CD012656

Keywords

MeSH

Medical Subject Headings (MeSH) Keywords

Medical Subject Headings Check Words

Adult; Child; Humans;

PICO

Population
Intervention
Comparison
Outcome

El uso y la enseñanza del modelo PICO están muy extendidos en el ámbito de la atención sanitaria basada en la evidencia para formular preguntas y estrategias de búsqueda y para caracterizar estudios o metanálisis clínicos. PICO son las siglas en inglés de cuatro posibles componentes de una pregunta de investigación: paciente, población o problema; intervención; comparación; desenlace (outcome).

Para saber más sobre el uso del modelo PICO, puede consultar el Manual Cochrane.

Logic framework: treatment outcome pathways in Plasmodium vivax liver hypnozoite infection
Figuras y tablas -
Figure 1

Logic framework: treatment outcome pathways in Plasmodium vivax liver hypnozoite infection

Ir a la figura del protocoloAbrir en una pestaña nueva
Table 1. Data extraction: Grouping of comparisons to address the review objectives

Objective

Intervention

Control

Are higher doses more effective (0.5 mg/kg or 30 mg primaquine/day for 14 days), in all areas, or only in areas where they are standard treatment (Asia, Pacific)?

Blood‐stage antimalarial drug with primaquine 0.5 mg/kg (30 mg) per day for 14 days (total dose 420 mg)

Both intervention and control groups must have received the same treatment: either CQ or ACT for the blood‐borne stage of infection.

Blood‐stage antimalarial drug with primaquine 0.25 mg/kg (15 mg) per day for 14 days (total dose 210 mg)

Both intervention and control groups must have received the same treatment: either CQ or ACT for the blood‐borne stage of infection.

Are shorter, higher dose regimes of primaquine over 7 days as effective as treatment over 14 days (is the total dose rather than the length of treatment the important factor)?

Blood‐stage antimalarial drug with primaquine 0.5 mg/kg (30 mg) per day for 7 days (total dose 210 mg)

Both intervention and control groups must have received the same treatment: either CQ or ACT for the blood‐borne stage of infection.

Are weekly dosing regimens (0.75 mg/kg or 45 mg/week for 8 weeks) as effective?

Blood‐stage antimalarial drug with primaquine 0.75/kg (45 mg) per week for 8 weeks (total dose 360 mg)

CQ = Chloroquine

ACT = Artemisinin‐based combination therapy
Figuras y tablas -
Table 1. Data extraction: Grouping of comparisons to address the review objectives
Ir a la tabla del protocolo